The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies

Carmelo Gurnari 1,2,3 , Simona Pagliuca 1 and Valeria Visconte 1,*

1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA; carmelogurnari31@gmail.com (C.G.); paglius@ccf.org (S.P.)
2 Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy
3 Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, 00133 Rome, Italy
* Correspondence: visconv@ccf.org

Abstract: The study of metabolic deregulation in myeloid malignancies has led to the investigation of metabolic-targeted therapies considering that cells undergoing leukemic transformation have excessive energy demands for growth and proliferation. However, the most difficult challenge in agents targeting metabolism is to determine a window of therapeutic opportunities between normal and neoplastic cells, considering that all or most of the metabolic pathways important for cancer ontogeny may also regulate physiological cell functions. Targeted therapies have used the properties of leukemic cells to produce altered metabolic products when mutated. This is the case of IDH1/2 mutations generating the abnormal conversion of α-ketoglutarate (KG) to 2-hydroxyglutarate, an oncometabolite inhibiting KG-dependent enzymes, such as the TET family of genes (pivotal in characterizing leukemia cells either by mutations, e.g., TET2, or by altered expression, e.g., TET1/2/3). Additional observations derive from the high sensitivity of leukemic cells to oxidative phosphorylation and its amelioration using BCL-2 inhibitors (Venetoclax) or by disrupting the mitochondrial respiration. More recently, nicotinamide metabolism has been described to mediate resistance to Venetoclax in patients with acute myeloid leukemia. Herein, we will provide an overview of the latest research on the link between metabolic pathways interactome and leukemogenesis with a comprehensive analysis of the metabolic consequences of driver genetic lesions and exemplificative druggable pathways.

Keywords: myeloid malignancies; TET2 mutations; IDH1/2 mutations; venetoclax; nicotinamide

1. Introduction

During normal cellular development, metabolism is one of the principal modalities to produce energy. In fact, from cell birth to differentiation, cell metabolism, together with a switch in transcriptional factors and cytokine release in some instances, dictate cell fate. As an example, hematopoietic stem cells (HSCs) adapt the balance between survival and quiescence by keeping a low oxygen status, stabilizing the hypoxia-inducible factor (HIF-1α), and stimulate glycolysis activating enzymes regulating glucose uptake (glucose transporter 1, Glut1) and pyruvate synthesis (Lactate Dehydrogenase A, LDHA). The main demand of HSCs is maintaining themselves in a quiescent status which is easily reached by using low energetic power through glycolysis [1]. Studies have shown how changes in metabolism, specifically in the glycolytic process, are notably present in acute myeloid leukemia (AML) [2–4]. Indeed history goes back to the first measurements of tumor metabolism when Nobel Prize in Physiology and Medicine Otto Warburg discovered that malignant cells favor the production of lactic acid (anaerobic glycolysis) in the TCA cycle as a source of ATP production. Leukemia-initiating cells (LICs) have an increased glycolytic flux mediated by AMP-activated kinase (AMPK) activation and decreased levels...
of autophagic activity. Often, increased glycolytic activity has been associated with resistance to pharmacologic agents [5]. Moreover, the high flux of glucose has been linked to increased glucose-6-phosphate dehydrogenase (G6PD) and consequently to unfavorable prognosis. Indeed FLT3 inhibitors have been shown to inactivate G6PD in FLT3 mutant AML [6]. Because of the high demand for glucose, frequently AML cells switch to the use of fructose as an energy source, suggesting that the inhibition of fructose uptake might be a way to starve AML cells and reduce their malignant potential.

Leukemia stem cells (LSC) rely mainly on oxidative phosphorylation (OXPHOS) through BCL-2, suggesting the basis to target BCL-2-dependent pathways [7]. Another modality of controlling LSCs to use OXPHOS is through glutamine metabolism. In fact, inhibition of the conversion of glutamine in glutamate by blocking glutaminases is able to arrest leukemic activity, and targeting glutamine conversion has been found efficient in synergy with BCL-2 inhibition [8]. Overproduction of endogenous reactive oxygen species is also another option to help AML cells to promote blast proliferation. Studies aiming to describe the global metabolic profiles and redox status of AML cells have shown differences in metabolic spectra between diverse cytogenetic and molecular subtypes [9,10]. Moreover, the presence of specific metabolites has been associated with prognosis and identified as markers of aggressiveness (phosphocholine and phosphoethanolamine) and chemoresistance (overexpression of glutathione). Altogether the deregulation of metabolic pathways in AML might contribute to therapy-resistance and relapse.

Targeting the metabolic pathway is feasible but mostly depends on a fine and specific targeting of only altered processes, given the importance of metabolic functions in normal cells. In this line, the concomitant use of metabolic pathways inhibitors and differentiation agents (BCL-2 inhibitors and hypomethylating agents, HMA) represents a promising avenue in drug discovery. Recently the combination of the data obtained from the Reactome and KEGG pathway and The Cancer Genome Atlas has defined the interaction between metabolic pathways and molecular and transcriptomic signatures in all cancers, including myeloid malignancies.

Here, we provide examples of the link between altered metabolism and leukemogenic potential, focusing on some of the major mutations in myeloid genes (e.g., TET2 and IDH1/2) generating important biological consequences in a variety of cellular processes. Moreover, we will also review available therapeutic options and examples of dysregulation in genes involved in metabolism (Figures 1 and 2).
Figure 1. View at a glance of the landscape of the metabolic interactions between genes and pathways discussed in the manuscript. On the left, the intrinsic apoptotic pathway highlighted by BCL-2 as the pivotal player (targeted by Venetoclax) and the interaction with BAX and BIM to initiate the caspases cascade to trigger apoptosis. On the right, the interaction between the Krebs cycle (TCA), the convergence of IDH1/2 generating α-ketoglutarate, 2-hydroxyglutarate and the TET family of genes, which finally impacts DNA methylation. Included are also the available drugs used to target the depicted pathways. On the top, in relapsed/refractory (R/R) acute myeloid leukemia (AML), the interconnection between the increase in NAD metabolism generated by alteration of oxidative phosphorylation and Venetoclax resistance is shown together with proposed actionable target agents (e.g., KPT-9274) inhibiting Nicotinamide Phosphoribosyltransferase (NAMPT). Images were generated using BioRender.
Figure 2. TET functions and their alterations in myeloid malignancies. DNA methyltransferases (DNMTs) initiate cytosine methylation with conversion to 5-methylcytosine (5-mc). TET proteins progressively oxidize 5-mc to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-FoC), and 5-carboxylcytosine (5-CaC) creating a pool of TET-oxidized products (TDOP). 5-hmC can be reverted to cytosine via passive dilution while 5-FoC and 5-CaC via thymine DNA glycosylase-mediated base excision repair. Somatic TET2 mutations create an imbalance in cellular DNA methylation through the disruption of the aforementioned mechanism with alteration of chromatin and thereby consequences on expression of genes regulating cell division and self-renewal. Images were generated using BioRender.

2. The Metabolomics of TET Family of Genes

The Ten-Eleven Translocation (TET) gene family (TET1, TET2, and TET3) encodes for dioxygenase enzymes catalyzing the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) [11]. The first discovered gene was TET1, identified as a partner of mixed-lineage leukemia (MLL/KMT2A) gene in a case of infant AML carrying a t(10:11) (q22;q23) translocation [12,13]. The finding of the dioxygenase function of TET1 led to the identification of the other two members of the TET family, TET2 and TET3 [14,15].

The carboxyl (C)-terminus of all three TET family members harbors the oxygenase catalytic domain and the binding sites for 2-oxoglutarate (α-KG) and Fe²⁺, which are both critical cofactors for TET oxidative activity [16]. TET proteins progressively oxidize 5-mC to 5-hmC, 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC), creating a pool of TET-dependent 5-mC-DNA oxidation products (TDOP) which ultimately can be reverted to cytosine via thymine DNA glycosylase-mediated base excision repair [16,17].(Figure 2)

Therefore, TET proteins are critical regulators of DNA demethylation via the generation of 5-hmC, ultimately leading to enhanced gene expression and transcription profiles responsible for cell proliferation and survival [18–20]. As the role of the TET family of genes is highly crucial during cell development, any impairment either by genetic lesions or altered expression might impact the normal fate of the cells. Indeed, high levels of expression of TET family proteins and, as a consequence, of 5-hmC have also been found to
be crucial for embryonic stem cells, determining cell fate and development with redundant functions [21,22]. As demonstrated by knockout (KO) experiments in mice, triple Tet1/2/3 inactivation led to embryonic lethality while other Tet1 and/or Tet2 KO configurations were not completely disruptive [21,23,24]. TET2 haploinsufficiency altered HSC reprogramming into induced pluripotent stem cells, as demonstrated by an experiment of TET2 silencing via short hairpin RNA with different consequences according to the type of TET2 mutation present [25]. Thus, while the pivotal role of TET2 mutations is underlined by their high frequency in myeloid disorders, including AML, the lack of molecular lesions in the homologous TET1/TET3 genes is probably explicable with a distinct tissue-specific expression and differences in the specific metabolic consequences derived from their imbalance [26].

2.1. TET2: A Pivotal Gene in Myeloid Malignancies

Somatic TET2 mutations are commonly found in myeloid malignancies (MN) at frequencies varying according to disease subtypes. In myelodysplastic syndromes (MDS) and AML, TET2 mutations are present in 20%–30% of cases, ranging up to 50% in patients affected by chronic myelomonocytic leukemia (CMML) [27–29]. Mutations are mainly loss-of-function (either frameshift or nonsense) affecting the coding region or missense mutations mapping in critical sites required for the enzymatic activity [30]. The prognostic role of TET2 lesions has been controversial because of their high frequency, their heterogeneity, and the variability of the concurrent genetic lesions, all characteristics contributing to shaping the fate of individual patients and ultimately precluding a clear genotype/phenotype association [30]. Moreover, the discovery of mutations in myeloid genes in normal individual (referred to as CHIP, clonal hematopoiesis of indeterminate potential) at frequencies linearly correlated with age (age-related clonal hematopoiesis, ARCH) shed light on the process of myeloid evolution and provided clues on clonality and subclonal hierarchies in myeloid malignancies [31]. The occurrence of TET2 mutations in CHIP/ARCH is another confirmation of the importance of this gene in cell development. Together with additional sex combs-like 1 (ASXL1) and DNA methyltransferase 3 alpha (DNMT3A) genes, TET2 represents one of the most frequently mutated genes in CHIP/ARCH so that the three genes are referred to with the acronym DAT (DNMT3A/ASXL1/TET2) [31]. This finding, as well as the ubiquitous presence of TET2 mutations in hematological malignancies, indicate that TET2 lesions are mainly ancestral events occurring early in the course of the disease and contribute to the creation of a so-called “mutator phenotype”, by giving to the clone a proclivity for the acquisition of additional molecular lesions [32]. Indeed, our group demonstrated that in a cohort of 4930 patients with MNs, 1205 (24%) carried TET2 mutations, which were ancestral and probably deriving from TET2-mutant CHIP in >40% of cases [30]. Subclonal acquisition of new leukemogenic events was identified as a facilitating condition for later myeloid progression and disease phenotypic determination (dysplastic vs. proliferative), as underlined by the higher number of secondary mutational events in TET2-mutant vs. TET2 wild-type MN and in Tet2 murine models [30]. Of note, progressive TET2 inactivation was associated with disease progression and poor survival outcomes as demonstrated by the aforementioned tendency of TET2 mutant cases to accumulate additional hits in the same gene either resulting in biallelic mutations, deletions in hemizygous configurations, or uniparental disomies (UPDs) with homozygous mutations, with the latter two groups registering a negative impact on survival [30]. As a matter of fact, in another study focusing only on biallelic TET2-mutant MN, we confirmed that biallelic inactivation is frequently observed in MN and that this configuration is a typical feature of older patients with monocytosis (also outside the context of an overt CMML diagnosis), CMML, normal karyotype, and lower-risk disease. Therefore, biallelic TET2 inactivation led to a disease phenotype skewed towards higher odds of monocytic vs. dysplastic features consistent with its prevalence in CMML [33]. Development of a CMML-like disease in mice has been reported in the literature, confirming the role of TET2 in driving differentiation pressure towards a myelo-monocytic lineage consistent with the high frequency of TET2 mutations in patients with CMML [34–36]. The association of TET2
biallelic cases with lower-risk disease, rather than with a more aggressive phenotype as in the case of other TET2 double-hits configurations (deletions in hemizygous configurations or UPDs with homozygous mutations), may be explainable with compensatory TET1/TET3 stabilizing functions or acetylation mechanisms leading to increased TET2 protein stability [33]. The p300-mediated acetylation of key lysine residues (K110 and K111) at the amino (N)-terminus of TET2 enhances its functions and protects against DNA methylation during oxidative stress interacting with DNA methyltransferases (DNMTs) and regulating 5-mc/5-hmC balance [37]. The importance of metabolic events following TET2 loss-of-function mutations in the pathogenesis of MN is also outlined by data showing its general down-regulation in patients with MN and the down-regulation of its family members [38]. Of note, low expression levels of the TET2 gene may be found independently of the presence of its mutations [39–41]. Indeed TET2 expression and 5-hmC levels were found also decreased in pediatric MDS cases, a population known to be rarely mutated in TET2 gene [41]. TET2 expression levels have also been identified as a predictive and a prognostic biomarker in cytogenetically normal (CN)-AML [42]. Indeed, low TET2 expression had a negative impact on overall survival (OS) in both non-M3 and CN-AML (p = 0.016 and 0.044, respectively), although multivariable analysis confirmed these results only for the CN group [42]. Conversely, higher expression of TET1 at diagnosis was associated with poor clinical outcomes in a cohort of 360 CN-AML patients [43]. Finally, a recent study demonstrated that high TET3 expression was an independent factor for better OS and disease-free survival (DFS) in AML [44]. Of note, patients with lower TET3 expression undergoing hematopoietic stem cell transplant (HSCT) showed better OS and DFS than those who did not proceed to HSCT [44].

2.2. TET2 as an Actionable Target

Altogether, these data provide evidence that the TET family of genes, and in particular TET2, are actionable therapeutic targets in MN. In this line, recent findings suggested that ascorbic acid (AA) was able to restore some TET2 metabolic activities in vitro [45–47]. In addition, AA depletion in mice cooperated with Flt3-ITD mutations to accelerate leukemogenesis, whereas the reintroduction of dietary AA reversed this phenomenon by promoting Tet functions [46]. Moreover, AA was able to restore 5-hmC formation, drive DNA hypomethylation and expression of a TET2 gene signature, and ultimately suppressed leukemia progression in patient-derived xenografts (PDXs) [47]. Likewise, our group confirmed that long-term AA treatment prevented MN evolution in Tet2-deficient murine models [17]. However, TET2 loss due to catalytic domain lysine acetylation or missense mutations prevented this beneficial effect, which was restored by the additional use of class I and II histone deacetylase inhibitors [17]. Lower than normal AA levels have been found in patients with MN, and AA has been used at supraphysiological doses in a case of TET2 mutant AML, confirming its potential therapeutic role in TET2-mutant MN [48]. Based on these considerations, many clinical trials (NCT03682029, NCT03999723) are trying to incorporate AA in the therapeutic schemes of MN, and future data will clarify the best settings for patients suitable for this treatment option [49].

Taking into consideration the biological consequences of TET2 mutations, HMA constitutes a class of drugs currently available for patients with TET2-mutant MN. Studying a cohort of 213 MDS cases, Bejar et al. showed that TET2 mutant patients had an increased likelihood of response to HMA treatment [50]. Similarly, other studies, including ours, described a better response to HMAs in patients harboring TET2 mutations [51,52]. Indeed, as shown by competitive bone marrow transplantation experiments, HMA administration was able to significantly decrease Tet2-null cell proliferation advantage over wild-type cells (p = 0.002) [50].

Besides HMA, our group has recently developed a new therapeutic approach which entails the use of a TET-selective small-molecule inhibitor able to selectively suppress TET2-mutant cells in mouse models and TET2-mutated human leukemia xenografts while sparing normal cells [53].
Finally, in vitro and in vivo studies conducted in other models (hyperglycemic conditions) have depicted an impairment of the DNA 5-hydroxymethylome. TET2 has been identified as a substrate of the AMPK, which phosphorylates TET2 at serine 99. Increased glucose levels blocked AMPK-mediated phosphorylation at serine 99, causing the destabilization of TET2 followed by dysregulation of 5-hmC. This study also showed that administration of a biguanide (metformin) protected AMPK-mediated phosphorylation of serine 99 and increased TET2 stability and 5-hmC levels [54]. Similarly, studies conducted with AML have shown that AMPK is one of the major sensors of energy status and also for AML differentiation [55].

3. Isocitrate Dehydrogenase NADP(+) 1 and 2

Isocitrate Dehydrogenase NADP(+) 1 and 2 genes encode enzymes of the tricarboxylic acid cycle (TCA), and mutations in these genes have been found to contribute to cancer development and progression because of the disruption of cell metabolism [56,57]. The two isoforms of IDH1/2 metabolize isocitrate to α-KG in the mitochondrion (IDH2) as one of the steps of the Krebs cycle and in the cytoplasm (IDH1) [58]. Gain of function mutations in IDH1 or IDH2 result in a reduction in levels of α-KG and an increase in the formation of D-2-hydroxyglutarate (2-HG) [59,60]. α-KG represents one of the cofactors for several dioxygenases, such as the TET family of genes (see Section 2) and the Jumonji (Jmj) family of histone demethylases [61]. In general, α-KG is a crucial metabolic cofactor of histone and DNA demethylases, while 2-HG acts as a competitive inhibitor. The discovery of mutations of both IDH isoforms has led to the study of the interconnection between metabolism and epigenetics. IDH mutations are present in many cancers, including AML (around 20% of cases) [62]. Mutations are heterozygous and occur in substrate binding residues of IDH1 (R132H) and IDH2 (R140Q, R172K) [60]. Because of the nature of these mutations leading to the chemical formation of the oncometabolite 2-HG, several small-molecule inhibitors of the mutant form of both IDH have been developed and are showing good clinical responses [63,64]. Enasidenib and ivosidenib, IDH2 and IDH1 inhibitors respectively, were developed by Agios Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of adult relapsed or refractory AML with IDH2 and IDH1 mutations [65,66]. Despite response rates at a frequency of about 50% achieved when used as monotherapy, a fraction of patients develop resistance to this class of agents. Resistance mechanisms have been attributed to the presence of co-occurring mutations in the RAS-family of genes (FLT3, PTPN11, and KIT), RUNX1 and CEBPA, second site IDH1 mutations, and isoform switching [67–69]. Therefore, a combination strategy with HMA has been envisioned as an option of investigation in AML patients ineligible for intensive chemotherapy (NCT02677922). Preclinical work has suggested that the addition of azacitidine (AZA) to the IDH1 inhibitor, ivosidenib, enhances mutant IDH1 inhibition-related differentiation and apoptosis. Indeed its combination resulted in a durable response, with the most complete responders showing a disappearance of IDH1 mutations [70]. In fact, it was recently reported that the synergistic activity of the IDH1 inhibitor BAY1436032 with AZA in AML with IDH1 mutations enhances anti-leukemia activity by co-targeting metabolism and methylation [71]. BAY1436032 showed profound antileukemic activity in two separate mutant AML derived xenografts, and it is now under clinical investigation for AML with IDH1 mutations relapsed from or refractory to at least one previous line of therapy (NCT03127735). Inhibition of DNA methyltransferases and histones can also be achieved through loss-of-function mutations in the fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes producing immoderate doses of fumarate and succinate, which act as competitive inhibitors of α-KG-dependent dioxygenases [72].

4. Venetoclax: An Agent Indirectly Inhibiting the TCA Cycle

The intrinsic apoptotic pathway consists of the B-cell lymphoma-2 (BCL-2) family, including proteins with conservative BCL-2-like homology domains 1–4 (BH1–BH4). These proteins are classified as suppressors (BCL-2/A1, BCL-XL/W, and MCL-1), activators...
(BIM and PUMA), effectors (BAX and BAK), and sensitizers (NOXA) [73]. The activation of the apoptotic pathway converges to some of these proteins, which ultimately create pores in the mitochondrial outer membrane with the release of cytochrome C and the activation of caspase 9, causing cell death (Figure 1, left panel). Inhibition of BCL-2 started several years ago with the discovery of the importance of this pathway in OXPHOS and metabolism of quiescent LSCs and the development of ABT-737, ABT-263 (navitoclax), and recently, GX15-070 (obatoclax) [74]. All these compounds were pan-inhibitors, with some causing thrombocytopenia as off-target effects involving BCL-XL and limited applicability to humans [75].

Venetoclax (ABT-199; VEN) is an oral BCL-2 selective BH3-mimetic agent which has been shown to inhibit mitochondrial metabolism by impairing TCA cycle activity, leading to the activation of reductive carboxylation [76,77]. As a result, VEN causes cellular metabolic reprogramming. Chemically this drug was developed to selectively target BCL-2, skipping the targeting of other homology BH family of proteins. BH3 profiling showed a positive correlation between VEN sensitivity and BCL-2 dependence, promoting the investigation of combinational strategy. Indeed, a number of agents have been combined with VEN, from daunorubicin to HMAs, neddylation inhibitors (MNL4924), FLT3 inhibitors (e.g., quizartinib), and IDH2 inhibitors (e.g., enasidenib) [78]. These studies led to the approval of VEN by the FDA in combination with HMAs (AZA or decitabine) or low-dose cytarabine as a front-line treatment in older patients with AML or unfit for induction chemotherapy [79]. VEN and HMAs, already possessing activity as single agents, showed higher rates of CR in combination in both treatment-naive and relapsed patients making this combo particularly promising. In particular, treatment with VEN and AZA led to superior clinical outcomes in older patients with AML [80]. Mechanistic studies showed that this treatment produces the inhibition of the electron transport chain complex II, disruption of the TCA cycle, and suppression of OXPHOS. Indeed OXPHOS is inhibited in vivo, and LSCs are eradicated in patients undergoing VEN/AZA treatment [81]. Additional confirmations derive from other data showing that the combination of the two drugs seems to decrease amino acid uptake, reducing OXPHOS and leading to LSC apoptosis [82]. However, VEN resistance has been linked to metabolic changes preventing cytochrome c release, and recent data on the co-targeting of mitochondrial complex I and BCL-2 showed promising results in AML cells reliant on OXPHOS [83]. In patients with R/R AML, the lower response to VEN/AZA has been correlated with increased levels of NAM and higher energy metabolism [81]. A schematic representation of the interplay between NAMPT, OXPHOS, and glycolysis pathways and their role in resistance to VEN is shown in Figure 1.

Di Nardo and colleagues’ data on VEN in combination with HMAs in the treatment-naive elderly AML demonstrated that this combination was effective in most cytogenetic subgroups, including in patients harboring high-risk molecular features, IDH1/2 lesions, and secondary AML [80,84]. However, ongoing studies are focusing on investigating the mechanisms behind the resistance of about a third of patients treated with VEN.

5. Nicotinamide: Pleiotropic Activity and Therapeutic Avenues

NAM adenine dinucleotide (NAD+) is an essential niacin-derived reduction-oxidation (redox) cofactor and cosubstrate for multiple enzymatic activities, playing a fundamental role in gene-regulatory, signaling, metabolic, and cellular homeostasis pathways, as well as in aging and diseases [85].

Our body is able to synthesize NAD+ from various dietary sources. A de novo pathway, starting from the metabolism of tryptophan degradation, uses quinolinic acid (QUIN). Others, described as salvage pathways, use dietary niacin (vitamin B3)—nicotinic acid (NA) and its pyridine-nucleoside or amide forms of nicotinamide riboside (NR) and nicotinamide (NAM), respectively. NAM is also produced from the reactions carried out by the enzymes that use NAD+ as a substrate, splitting the molecule at the N-glycosidic bond [86–88]. Three pathways have been identified for NAD+ utilization: the sirtuin (SIRT) mediated pathway and the ADP ribosylation—mono and poly-ribosylation—and cyclic
Within the mitochondria, NAD accepts electrons from a variety of sources and transfers them to complex I of the electron transport chain, ultimately resulting in the generation of ATP. NAD influences fuel selection, circadian rhythms, cell survival, and self-renewal under stress [90–92]. Although mechanisms of generating and maintaining the mitochondrial NAD pool are not completely understood, growing evidence shows that mitochondria not only can import NAD directly through an unrecognized membrane transporter but also have their specific nicotinamide mononucleotide adenylyltransferases (NMNATs) enzyme, able to convert nicotinamide mononucleotide (NMN) to NAD [93,94]. It is well established that HSCs tune cell cycle, apoptosis, and oxidative stress, which are at the basis of their balance among processes of quiescence, differentiation, and self-renewal. Deregulation of this balance can result in the development of blood disorders [95,96]. An interesting approach that is generating a growing body of evidence, both in vivo and in vitro, consists of using nicotinamide or NAD boosting agents as promoters of hematopoiesis [97–100]. The rationale for this approach is based on the stimulation of mitochondrial clearance in HSCs by increasing NAD+ content, a process at the basis of the self-renewal expansion supporting stress-induced hematopoiesis [101–103]. Mice supplemented with dietary NR boosted their hematopoietic progenitor compartments, showing a functional increase in short-term hematopoietic progenitors without affecting the self-renewing compartment of the long-term progenitors [97].

A recent phase I clinical trial has shown the efficacy of an expanded cord blood product (NiCord, NCT01816230) obtained after the supplementation of isolated CD133+ progenitors with nicotinamide and cytokines (including Flt3 ligand, stem cell factor, thrombopoietin, IL-6), infused after myeloablative conditioning [100]. This study showed significantly lower shorter neutrophil and platelet engraftment time compared to the non-expanded control group.

An ongoing phase I study (temporarily suspended during the COVID-19 pandemic), sponsored by the Case Comprehensive Cancer Center in Cleveland, aims to explore the role of NR in increasing donor-derived blood stem cell numbers in decreasing the engraftment time in other allogeneic stem cell transplant settings (NCT04332341).

Another interesting field of application in the setting of hematological neoplasms is the NAD+ capability of influencing the responsiveness to the cytotoxic effects elicited by DNA-damaging agents [104]. Genetic and pharmacological inhibition of NAM phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAM metabolism, demonstrated selective eradication of relapsed LSCs. Indeed, it has been shown that VEN in combination with AZA failed to eradicate LSCs in R/R patients with AML (Figure 1) [105]. Metabolomic analysis revealed that elevated nicotinamide metabolism in relapsed LSCs activates amino acid metabolism and fatty acid oxidation, ultimately driving OXPHOS and blocking the apoptotic effect of both VEN and AZA [105]. A study conducted by high-throughput flow cytometry-based drug screen against cells of an AML case identified agents that selectively depleted the CD34+CD38- fraction (markers of LSCs), including four structurally-unrelated NAMPT inhibitors (FK866, STF-118804, GMX1778, and KPT-9274). Therefore, NAMPT inhibition represented an effective modality to selectively target human LSCs by decreasing intracellular NAD+ levels and inducing apoptosis (Figure 1) [106].

6. Other Gene Pathways Interconnected to Cell Metabolism

Splicing factor 3b, subunit 1 (SF3B1). About 20% of patients with MDS and 60%–82% of patients with MDS with ringed sideroblasts (RS) and MDS/myeloproliferative neoplasms with RS and thrombocytosis harbor mutations in the splicing factor 3b, subunit 1 (SF3B1) [107–109]. The SF3B1 gene is a component of the RNA-splicing machinery and encodes a member of the U2 small nuclear ribonucleoprotein (U2snRNP), important in the branch point sequence recognition of pre-messenger RNA. A combination of transcriptomic and proteomic data has shown a number of metabolic genes altered in SF3B1 mutant cells, such as a decrease in the mitochondrial complex III of the electron chain transport regulated by the ubiquinol-cytochrome c reductase complex assembly factor 1 (UBCC).
Moreover, SF3B1 mutant cells presented lower citric acid metabolites and abnormal splicing of mitochondrial enzymes (DLST). Interestingly, SF3B1 mutant cells were characterized by missplicing and, therefore, deregulation of another metabolic gene, phosphoglycerase dehydrogenase (PHGDH), an enzyme controlling the nonessential amino acid serine. The exogenous supplementation of PHGDH was able to rescue the growth impairment of SF3B1 mutant cells [110]. Drugs under investigation for patients with MN and splicing factors mutations are included in Table 1.

Table 1. Therapeutic strategies, targets, and mechanisms in myeloid malignancies.

| Metabolic Pathway | Genes Involved | Gene Mutation | Pathogenic Mechanisms | Drugs | Pharmacological Mechanism | Clinical Trial |
|-------------------|----------------|---------------|-----------------------|-------|---------------------------|---------------|
| TET metabolism    | TET1, TET2, and TET3 | TET2 | Altered DNA-methylation | Bobcat339 and TETi76 | TET2-mutant suppression | - |
|                   |                |               |                       | Ascorbate | Restoration of 5-hmC formation, DNA-hypomethylation | NCT03682029; NCT03999723 |
|                   |                |               |                       | HMA | DNA-hypomethylation | - |
| TCA cycle         | IDH1 and IDH2 | IDH1 and IDH2 | Reduction in α-KG levels and increased 2-HG | Ivosidenib * Enasidenib * Venetoclax * | IDH1 inhibitor IDH2 inhibitor BCL-2 inhibitor | NCT03839771; NCT03839771; NCT04628026; NCT04628026 |
|                   |                |               |                       | Phosphohydroxypyruvate | Serine synthesis pathway Inhibition of early stages of spliceosome cascade Intron retention and exon skipping | NCT02841540; NCT01692197 |
| Mitochondrial activity | SF3B1 and PHGDH | SF3B1 | Abnormal splicing of mitochondrial enzymes | H3B-8800 E7070 | | |
| Creatine kinase pathway | EVII, RUNX1, and CKMT1 | MECOM | Apoptosis and cell differentiation | Cyclocreatine | Inhibition of CKMT1 | - |
| OXPHOS            | FLT3 | FLT3 | OXPHOS/glycolysis imbalance | AC220 (Quazartinib)+ IACS-010759 | Restoration of ATP levels | NCT02882321 |
| NAM metabolism    | Multiple genes encoding for enzymes of OXPHOS | NA | OXPHOS, amino acid metabolism alteration | OT-82, KPT-9274 | NAMPT inhibitors | NCT03921879; NCT02702492 |

- - not available; α-KG, α-ketoglutarate; 2-HG, 2-hydroxyglutarate; BCL-2, B-cell lymphoma-2; OXPHOS, Oxidative phosphorylation; TET, Ten-Eleven Translocation 1,2,3; IDH, Isocitrate Dehydrogenase 1,2; SF3B1, Splicing factor 3b, subunit 1; PHGDG, phosphoglycerase dehydrogenase; MECOM, MDS1 and EVI1 complex locus; RUNX1, runt-related transcription factor 1; CKMT1, creatine kinase mitochondrial 1; FLT3, FMS-like tyrosine kinase 3. * These agents have been FDA-approved for clinical use.

FMS-like tyrosine kinase 3 (FLT3). FLT3 mutations, mainly internal tandem duplications (FLT3-ITD), are found in 30% of AML patients and confer a poor prognosis and increased relapse rate. Studies conducted in murine cells have shown that cells overexpressing FLT3-ITD have increased glycolytic activity favoring ATP transfer from OXPHOS and promoting glycolysis [111]. Moreover, synthetic lethality screens conducted in human AML cells harboring FLT3-ITD mutations have found a number of metabolic genes (e.g., ATM and G6PD) able to sensitize FLT3-ITD cells to FLT3 inhibitors [6]. More recently, studies have shown that the combination of an FLT3 inhibitor (AC220) with OXPHOS inhibitors or glutaminase inhibitors was effective in models of FLT3 mutant AML [112,113].

MDS1 and EVI1 complex locus (MECOM alias EVI1). The EVI1 gene encodes a transcriptional regulator and oncoprotein involved in hematopoiesis, apoptosis, and cell differentiation [114]. The protein represses the myeloid lineage-committed regulator RUNX1 leading to the expression of creatine kinase mitochondrial 1 (CKMT1), which is involved in
the conversion of arginine into creatinine. In xenograft models of AML expressing EVI1, inhibition of CKMT1 pharmacologically or via genetic knockout blocks ATP production and extends the life span of mutant mice [114].

All current therapeutic applications, their target genes, and mechanisms are shown in Table 1.

7. Conclusions

Myeloid malignancies present with a distinct metabolomic signature. Targeting metabolic pathways has become a potent therapeutic strategy for this group of disorders. The biological basis of this approach resides in the metabolic regulation of normal hematopoiesis and their alterations. Seminal studies (cited in this review) have described the minimal disturbances leading to altered metabolism. Current pharmacologic agents providing a window of response to patients with AML exemplify that targeting the metabolome is feasible, and in combination with currently approved agents, might increase the panoply of agents for patients failing first therapeutic approaches.

Author Contributions: C.G., S.P., and V.V. conceived the idea and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: For support, we thank the AA and MDSIF, VeloSano Pilot Award, and Vera and Joseph Dresner Foundation–MDS (to V.V.), American Italian Cancer Foundation (to C.G.) and Italian Society of Hematology, Fondation ARC pour la recherche sur le Cancer and Philippe Foundation (to S.P.).

Conflicts of Interest: The authors declare no conflict of interest.

# References

1. Ito, K.; Bonora, M.; Ito, K. Metabolism as master of hematopoietic stem cell fate. *Int. J. Hematol.* 2019, 109, 18–27. [CrossRef]
2. Kreitz, J.; Schönfeld, C.; Seibert, M.; Stolp, V.; Alshamleh, I.; Oellerich, T.; Steffen, B.; Schwab, H.; Schnütgen, F.; Kurre, N.; et al. Metabolic Plasticity of Acute Myeloid Leukemia. *Cells* 2019, 8, 805. [CrossRef] [PubMed]
3. Castro, I.; Sampaio-Marques, B.; Ludovico, P. Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. *Cells* 2019, 8, 967. [CrossRef] [PubMed]
4. Chapuis, N.; Poulain, L.; Birsen, R.; Tamburini, J.; Bouscary, D. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. *Front. Oncol.* 2019, 9. [CrossRef]
5. Saito, Y.; Chapple, R.H.; Lin, A.; Kitano, A.; Nakada, D. AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. *Cell Stem Cell* 2015, 17, 585–596. [CrossRef]
6. Cosentino, C.; Grieco, D.; Costanzo, V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. *EMBO J.* 2011, 30, 546–555. [CrossRef]
7. Han, L.; Cavazos, A.; Baran, N.; Zhang, Q.; Kuruvilla, V.M.; Gay, J.P.; Feng, N.; Battula, V.L.; Kantarjian, H.M.; Daver, N.G.; et al. Mitochondrial Oxsphos as Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy: Survival Benefit by Complex I Inhibition with Iacs-010759. *Blood* 2019, 134, 5161. [CrossRef]
8. Jacque, N.; Ronchetti, A.M.; Larrue, C.; Meunier, G.; Birsen, R.; Willems, L.; Saldan, E.; Decrooq, J.; Maciel, T.T.; Lambert, M.; et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. *Blood* 2015, 126, 1346–1356. [CrossRef] [PubMed]
9. DiNardo, C.D.; Cortes, J.E. Mutations in AML: Prognostic and therapeutic implications. *Hematol. Am. Soc. Hematol. Educ. Progr.* 2016, 2016, 348–355. [CrossRef] [PubMed]
10. Bassal, M.A.; Leo, P.; Samarawera, S.E.; Maung, K.Z.Y.; Babic, M.; Venugopal, P.; Cheah, J.; Hahn, C.N.; Scott, H.S.; Glazov, E.; et al. Metabolic Profiling of Adult Acute Myeloid Leukemia (AML). *Blood* 2016, 128, 1684. [CrossRef]
11. Chiba, S. Dysregulation of TET2 in hematologic malignancies. *Int. J. Hematol.* 2017, 105, 17–22. [CrossRef]
12. Lorschbach, R.B.; Moore, J.; Mathew, S.; Raimondi, S.C.; Mukatira, S.T.; Downing, J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). *Leukemia* 2003, 17, 637–641. [CrossRef]
13. Ono, R.; Taki, T.; Taketani, T.; Taniwaki, M.; Kobayashi, H.; Hayashi, Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). *Cancer Res.* 2002, 62, 4075–4080.
14. Ko, M.; Huang, Y.; Jankowska, A.M.; Pape, U.J.; Tahiliani, M.; Bandukwala, H.S.; An, J.; Lamperti, E.D.; Koh, K.P.; Ganetzky, R.; et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature* 2010, 468, 839–843. [CrossRef] [PubMed]
15. He, Y.F.; Li, B.Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-mediated formation of 5-carboxycytosine and its excision by TDG in mammalian DNA. *Science* 2011, 333, 1303–1307. [CrossRef] [PubMed]
16. Kohli, R.M.; Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature* 2013, 502, 472–479. [CrossRef]

17. Guan, Y.; Greenberg, E.F.; Hasipek, M.; Chen, S.; Liu, X.; Kerr, C.M.; Gackowski, D.; Zarakowska, E.; Radivojevitch, T.; Gu, X.; et al. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. *Commun. Biol.* 2020, 3, 493. [CrossRef] [PubMed]

18. Bochtler, M.; Kolano, A.; Xu, G.L. DNA demethylation pathways: Additional players and regulators. *BioEssays* 2017, 39, 1–13. [CrossRef]

19. Verma, N.; Pan, H.; Doré, L.C.; Shukla, A.; Li, Q.V.; Pelham-Webb, B.; Teijeiro, V.; González, F.; Krivtsov, A.; Chang, C.J.; et al. TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. *Nat. Genet.* 2018, 50, 83–95. [CrossRef]

20. Zheng, G.; Fu, Y.; He, C. Nucleic acid oxidation in DNA damage repair and epigenetics. *Chem. Rev.* 2014, 114, 4602–4620. [CrossRef] [PubMed]

21. Dawlaty, M.M.; Breiling, A.; Le, T.; Barrasa, M.I.; Raddatz, G.; Gao, Q.; Powell, B.E.; Cheng, A.W.; Faull, K.F.; Lyko, F.; et al. Loss of TET enzymes compromises proper differentiation of embryonic stem cells. *Dev. Cell* 2014, 29, 102–111. [CrossRef]

22. Ito, S.; D’Alessio, A.C.; Taranova, O.V.; Hong, K.; Sowers, L.C.; Ogawa, S.; et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell* 2011, 20, 25–38. [CrossRef] [PubMed]

23. Quivoron, C.; Couronné, L.; Della Valle, V.; Lopez, C.K.; Plo, I.; Wagner-Ballon, O.; Do Cruzeiro, M.; Delhommeau, F.; Arnulf, B.; Stern, M.H.; et al. TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. *Stem Cell Rep.* 2020, 44, 101755. [CrossRef]

24. Guan, Y.; Hasipek, M.; Tiwari, A.D.; Maciejewski, J.P.; Jha, B.K. TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. *Semin. Hematol.* 2021, 58, 27–34. [CrossRef]

25. Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bulli, N.; et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2016, 374, 2209–2221. [CrossRef]

26. Haferlach, T.; Nagata, Y.; Grossmann, V.; Okuno, Y.; Bacher, U.; Nagea, G.; Schnittert, S.; Sanada, M.; Kon, A.; Alpermann, T.; et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia* 2014, 28, 241–247. [CrossRef]

27. Coltro, G.; Mangaonkar, A.A.; Lasho, T.L.; Finke, C.M.; Pophali, P.; Carr, R.; Gangat, N.; Binder, M.; Pardanani, A.; Fernandez-Zapico, M.; et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. *Leukemia* 2020, 34, 1407–1421. [CrossRef]

28. Hirsch, C.M.; Nazha, A.; Kneen, K.; Abazeed, M.E.; Meggendorfer, M.; Przychodzen, B.P.; Nadarajah, N.; Adema, V.; Nagata, Y.; Goyal, A.; et al. Consequences of mutant TET2 on clonality and subclonal hierarchy. *Leukemia* 2018, 32, 1751–1761. [CrossRef]

29. Gurnari, C.; Fabiani, E.; Falconi, G.; Travaglini, S.; Ottone, T.; Cristiano, A.; Voso, M.T. From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. *Biologics* 2021, 10, 128. [CrossRef] [PubMed]

30. Pan, F.; Wingo, T.S.; Zhao, Z.; Gao, R.; Makishima, H.; Qu, G.; Lin, L.; Yu, M.; Ortega, J.R.; Wang, J.; et al. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nat. Commun.* 2017, 8, 15102. [CrossRef] [PubMed]

31. Awada, H.; Nagata, Y.; Goyal, Á.; Asad, M.F.; Patel, B.; Hirsch, C.M.; Kuzmanovic, T.; Guan, Y.; Przychodzen, B.P.; Aty, M.; et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. *Blood Adv.* 2019, 3, 339–349. [CrossRef]

32. Moran-Crusio, K.; Reavie, L.; Shih, A.; Abdel-Wahab, O.; Ndiaye-Lobry, D.; Lobry, C.; Figueroa, M.E.; Vasanthakumar, A.; Patel, J.; Zhao, X.; et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell* 2011, 20, 25–61. [CrossRef] [PubMed]

33. Li, Z.; Cai, X.; Cai, C.L.; Wang, J.; Zhang, W.; Petersen, B.E.; Yang, F.C.; Xu, M. Deletion of TET2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of hematoid malignancies. *Blood* 2011, 118, 4509–4518. [CrossRef] [PubMed]

34. Pernier, E.; Almiré, C.; Mokrani, H.; Vasanthakumar, A.; Simon, A.; da Costa Reis Monte Mor, B.; Massé, À.; Le Couédic, J.P.; Pendent, F.; Carbonne, B.; et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. *Blood* 2011, 118, 2551–2555. [CrossRef]

35. Zhang, Y.W.; Wang, Z.; Xie, W.; Cai, Y.; Xia, L.; Easwaran, H.; Luo, J.; Yen, R.C.; Li, Y.; Baylin, S.B. Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. *Mol. Cell* 2017, 65, 323–335. [CrossRef]

36. Scopim-Ribeiro, R.; Machado-Neto, J.A.; Campos Pde, M.; Silva, C.A.; Favaro, P.; Lorand-Metze, I.; Costa, F.F.; Saad, S.T.; Traina, F. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. *Eur. J. Haematol.* 2015, 94, 413–418. [CrossRef]

37. Scopim-Ribeiro, R.; Machado-Neto, J.A.; de Melo Campos, P.; Niemann, F.S.; Lorand-Metze, I.; Costa, F.F.; Olalla Saad, S.T.; Traina, F. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. *Diagn. Pathol.* 2016, 11, 28. [CrossRef]
40. Jankowska, A.M.; Szpurka, H.; Tiu, R.V.; Makishima, H.; Afable, M.; Huh, J.; O’Keefe, C.L.; Ganetzky, R.; McDevitt, M.A.; Maciejewski, J.P. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. *Blood* 2009, 113, 6403–6410. [CrossRef]

41. Coutinho, D.F.; Monte-Mór, B.C.; Viana, D.T.; Rouxinol, S.T.; Batalha, A.B.; Bueno, A.P.; Boulhos, A.M.; Fernandez, T.S.; Pombo-de-Oliveira, M.S.; Gutiáryma, L.M.; et al. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood. *Leuk. Res.* 2015, 39, 1103–1108. [CrossRef]

42. Zhang, T.J.; Zhou, J.D.; Yang, D.Q.; Wang, Y.X.; Wen, X.M.; Guo, H.; Yang, L.; Lian, X.Y.; Lin, J.; Qian, J. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. *J. Cell. Physiol.* 2018, 233, 5838–5846. [CrossRef]

43. Wang, J.; Li, F.; Ma, Z.; Yu, M.; Guo, Q.; Huang, J.; Yu, W.; Wang, Y.; Jin, J. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts. *EBiomedicine* 2018, 28, 90–96. [CrossRef] [PubMed]

44. Zhang, T.; Zhao, Y.; Zhao, Y.; Zhou, J. Expression and prognosis analysis of TET family in acute myeloid leukemia. *Aging* 2020, 12, 5031–5047. [CrossRef] [PubMed]

45. Peng, D.; Ge, G.; Gong, Y.; Zhan, Y.; He, S.; Guan, B.; Li, Y.; Xu, Z.; Hao, H.; He, Z.; et al. Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer. *Clin. Epigen.* 2018, 10, 94. [CrossRef] [PubMed]

46. Agathocleous, M.; Meacham, C.E.; Burgess, R.J.; Piskounova, E.; Zhao, Z.; Crane, G.M.; Cowin, B.L.; Bruner, E.; Murphy, M.M.; Chen, W.; et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. *Nature* 2017, 549, 476–481. [CrossRef] [PubMed]

47. Cimmino, L.; Dolgalev, I.; Wang, Y.; Yoshimi, A.; Martin, G.H.; Wang, J.; Ng, V.; Xia, B.; Witkowski, M.T.; Mitchell-Flack, M.; et al. Restoration of TET2 Function Blocks Ablerrant Self-Renewal and Leukemia Progression. *Cell* 2017, 170, 1079–1095.e20. [CrossRef]

48. Das, A.B.; Kakadia, P.M.; Wojcik, D.; Pemberton, L.; Browett, P.; Bohlander, S.K.; Vissers, M.C.M. Clinical remission following ascorbate administration in a case of acute myelologic leukemia with mutations in TET2 and WT1. *Blood Cancer J.* 2019, 9, 82. [CrossRef]

49. Aldoss, I.; Mark, L.; Vrona, J.; Ramezani, L.; Weitz, I.; Mohrbacher, A.M.; Douer, D. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. *Ann. Hematol.* 2014, 93, 1839–1843. [CrossRef] [PubMed]

50. Bejar, R.; Lord, A.; Stevenson, K.; Bar-Natan, M.; Pérez-Ladaga, A.; Zaneveld, J.; Wang, H.; Caughley, B.; Stojanov, P.; Getz, G.; et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood* 2014, 124, 2705–2712. [CrossRef]

51. Itzykson, R.; Kosmider, O.; Cluzeau, T.; Mansat-De Mas, V.; Dreyfus, F.; Beyne-Rauzy, O.; Quesnel, B.; Vey, N.; Gelsi-Boyer, V.; Raynaud, S.; et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia* 2011, 25, 1147–1152. [CrossRef] [PubMed]

52. Traina, F.; Visconte, V.; Elson, P.; Tabarroki, A.; Jankowska, A.M.; Hasrouni, E.; Sugimoto, Y.; Szpurka, H.; Makishima, H.; O’Keefe, C.L.; et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. *Leukemia* 2014, 28, 78–87. [CrossRef] [PubMed]

53. Guan, Y.; Tiwari, A.D.; Phillips, J.G.; Hasipek, M.; Grabowski, D.R.; Pagliuca, S.; Gopal, P.; Kerr, C.M.; Adema, V.; Radioveitch, T.; et al. A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxynogenase–Deficient Cells in Myeloid Neoplasms. *Blood Cancer Discov.* 2020, 9, 228–233. [CrossRef] [PubMed]

54. Wu, D.; Hu, D.; Chen, H.; Shi, G.; Fetahu, L.S.; Wu, F.; Rabidou, K.; Fang, R.; Tan, L.; Xu, S.; et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. *Nature* 2018, 559, 637–641. [CrossRef] [PubMed]

55. Jacquel, A.; Luciano, F.; Robert, G.; Auberger, P. Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation. *Int. J. Mol. Sci.* 2018, 19, 2991. [CrossRef] [PubMed]

56. Gurnari, C.; Voso, M.T.; Maciejewski, J.P.; Visconte, V. From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. *EBioMedicine* 2020, 59, 1030–1041. [CrossRef] [PubMed]

57. Han, M.; Jia, L.; Lv, W.; Wang, L.; Cui, W. Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. *Front. Oncol.* 2019, 9. [CrossRef]

58. Raineri, S.; Mellot, J. IDH1: Linking Metabolism and Epigenetics. *Front. Genet.* 2018, 9. [CrossRef] [PubMed]

59. Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010, 17, 225–234. [CrossRef] [PubMed]

60. Marcucci, G.; Maharry, K.; Wu, Y.; Zaidi, M.; Radmacher, M.D.; Mrózek, K.; Margeson, D.; Holland, K.B.; Whitman, S.P.; Becker, H.; Schwind, S.; et al. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. *J. Clin. Oncol.* 2010, 28, 2348–2355. [CrossRef]

61. Tran, K.A.; Dillingham, C.M.; Sridhara, R. The role of α-ketoglutarate-dependent proteins in pluripotency acquisition and maintenance. *J. Biol. Chem.* 2019, 294, 5408–5419. [CrossRef] [PubMed]

62. DiNardo, C.D.; Ravandi, F.; Agresta, S.; Konopleva, M.; Takahashi, K.; Kadia, T.; Routbort, M.; Patel, K.P.; Mark, B.; Pierce, S.; et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *Am. J. Hematol.* 2015, 90, 732–736. [CrossRef]
111. Ju, H.Q.; Zhan, G.; Huang, A.; Sun, Y.; Wén, S.; Yang, J.; Lu, W.H.; Xu, R.H.; Li, J.; Li, Y.; et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. *Leukemia* 2017, 31, 2143–2150. [CrossRef] [PubMed]

112. Gregory, M.A.; Nemkov, T.; Reisz, J.A.; Zaberezhnyy, V.; Hansen, K.C.; D’Alessandro, A.; DeGregori, J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. *Exp. Hematol.* 2018, 58, 52–58. [CrossRef] [PubMed]

113. Alvarez-Calderon, F.; Gregory, M.A.; Pham-Danis, C.; DeRyckere, D.; Stevens, B.M.; Zaberezhnyy, V.; Hill, A.A.; Gemta, L.; Kumar, A.; Kumar, V.; et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2015, 21, 1360–1372. [CrossRef] [PubMed]

114. Fenouille, N.; Bassil, C.F.; Ben-Sahra, I.; Benajiba, L.; Alexe, G.; Ramos, A.; Pikman, Y.; Conway, A.S.; Burgess, M.R.; Li, Q.; et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. *Nat. Med.* 2017, 23, 301–313. [CrossRef] [PubMed]